CRISPR Therapeutics

Public

Nasdaq: CRSP

CRISPR Therapeutics is a gene-editing company that co-developed Casgevy with Vertex. Its clinical pipeline includes in vivo editing programs for cardiovascular targets…

Most advanced: Approved/marketed productsVerified Sep 2026

Abstract editorial illustration of three parallel strands—one receiving a new segment, one being precisely snipped, one being dimmed—representing gene therapy, gene editing and RNA medicines.

Genome + Cells

Approved

Gene Editing, Gene Therapy, and RNA Medicines: Three Different Ways to Change an Outcome

In December 2023 the FDA approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. Here is how gene editing, gene therapy and RNA medicines differ, and what that approval does and doesn't prove.

Feature6 min readSep 19, 2026